66th ASH Annual Meeting: 617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies

Symposia: Acute Myeloid Leukemias: Commercially Available Therapies Oral and Poster Abstracts
Oral

Acute Myeloid Malignancies, AML, Combination therapy, Adult, Research, Clinical trials, Elderly, Clinical Research, Chemotherapy, Pediatric, Diseases, Therapy sequence, Treatment Considerations, Real-world evidence, Non-Biological therapies, Adverse Events, Myeloid Malignancies, Study Population, Human, Measurable Residual Disease

Hall B (San Diego Convention Center)

Moderators:

Shai Shimony, MD, Dana-Farber Cancer Institute and Catherine E. Lai, MD, Abramson Cancer Center, University of Pennsylvania

Disclosures:

Lai: Servier: Other: Advisory board; Daiichi: Other: Advisory board; BMS: Other: Advisory board, Research Funding; AbbVie: Consultancy, Other: Advisory board; Astellas: Consultancy; Rigel: Other: Advisory Board; Genentech: Other: Advisory Board; Jazz: Research Funding.

We picked 6 abstracts that represented a large number of patients with potentially practice changing implications with modifications to existing regimens that are currently used

9:30 AM

A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial

Priyanka Mehta, MD, FRCPath, MRCP¹^*, Roderick Murphy²^*, Saemi Park³^*, Nalina Dronamraju³^*, Tony Wagner⁴^*, Yana Lutska³^*, Stefan Faderl⁴, Ian Thomas⁵^*, Joanna Canham⁵^* and Alex Legg⁶^*

¹University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
²Jazz Pharmaceuticals, Oxford, United Kingdom
³Jazz Pharmaceuticals, Philadelphia, PA
⁴Jazz Pharmaceuticals, Palo Alto, CA
⁵Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
⁶Jazz Pharmaceuticals, Oxford, CA, United Kingdom

9:45 AM

Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Alex Bataller, MD, PhD¹^*, Hagop M. Kantarjian, MD², Alexandre Bazinet, MD¹^*, Jayastu Senapati, MD, DM, MBBS¹, Gautam Borthakur, MD³, Nicholas J. Short, MD¹, Elias Jabbour, MD⁴, Koichi Takahashi, MD, PhD⁵, Naval Daver, MD⁶, Ghayas C. Issa, MD¹, Courtney D. DiNardo, MD, MSc⁷, Naveen Pemmaraju, MD⁸, Nitin Jain, MD¹, Guillermo Montalban-Bravo, MD¹, Guillermo Garcia-Manero, MD¹, Farhad Ravandi, MBBS⁹ and Tapan M. Kadia, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²University of Texas MD Anderson Cancer Center, Houston, TX
³Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁸Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
⁹Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

10:00 AM

Venetoclax Combined with "7+3" Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Ioannis Mantzaris, MD^1,2, Matan Uriel, MD¹^*, Mendel Goldfinger²^*, Aditi Shastri, MD^3,4, Nishi Shah, MBBS, MPH¹, Kira Gritsman, MD, PhD^1,5, Noah Kornblum, MD¹, Lauren Shapiro, MD¹, R. Alejandro Sica, MD¹, Annemarie Munoz, RN²^*, Nicole Chambers, NP¹^*, Aradhika Dhawan¹^*, Karen Fehn, RN, BSN²^*, Balda Tirone, MHA¹^*, Lamisha Shah⁵^*, Shaunmonique Clark¹^*, Mimi Kim, Sc.D⁶^*, Chenxin Zhang⁶^*, Dennis L Cooper, MD², Amit Verma, MD^4,7, Marina Konopleva^8,9 and Eric J. Feldman, MD¹^*

¹Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
²Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
³Montefiore Medical Center, Bronx, NY
⁴Department of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx
⁵Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY
⁶Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY
⁷Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Health System, Inc., Bronx, NY
⁸Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx
⁹Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY

10:15 AM

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Jules Higué¹^*, Corentin Orvain²^*, Pierre-Yves Dumas, MD, PhD³^*, Pierre Peterlin⁴^*, Marie Anne Hospital, MD, PhD⁵^*, Sabrina Barriere⁶^*, Areti Chantzi⁷^*, Audrey Couturier, MD⁸^*, Martin Carre, MD⁹^*, Emmanuelle Tavernier, MD¹⁰^*, Eric Delabesse, MD, PhD¹¹^*, Audrey Bidet, MD¹²^*, Anne Bouvier¹³^*, Marie Joelle Mozziconacci¹⁴^*, Lauren Veronese, MD¹⁵^*, Cedric Pastoret, MD PhD¹⁶^*, Sylvie Tondeur¹⁷^*, Pascale Flandrin-Gresta¹⁸^*, Sébastien Lachot⁷^*, Sarah Bertoli, MD¹⁹^*, Arnaud Pigneux, MD, PhD²⁰^* and Christian Récher, MD, PhD²¹

¹Service d'Hematologie, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
²Maladies du Sang, CHU d’Angers, Angers, France
³Hôpital Haut-Lévèque, Hematology Department, CHU Bordeaux, Pessac, France
⁴Hematology Department, Hôtel-Dieu University Hospital, NANTES CEDEX 1, France
⁵Department of Hematology, Institut Paoli-Calmettes, Marseille, France
⁶Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
⁷Hematology Department, CHU de Tours, Tours, France
⁸CHU de Rennes, Rennes, France
⁹Clinical Hematology Department, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France
¹⁰Département d'hématologie Clinique et de Thérapie Cellulaire, CHU Saint-Etienne, Saint-Etienne, France
¹¹IUCT-Oncopole, Hematology Laboratory, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
¹²Laboratoire d’Hématologie Biologique, CHU Bordeaux, Bordeaux, France
¹³Angers University Hospital, ANGERS, AL, FRA
¹⁴Department of Biopathology, Institut Paoli-Calmettes, Marseille, France
¹⁵Centre Hospitalier Universitaire Clermont-Ferrand, Clermont Ferrrand, FRA
¹⁶Rennes University Hospital, RENNES, FRA
¹⁷Grenoble Alpes University Hospital, Grenoble, FRA
¹⁸University Hospital of Saint-Etienne, Saint-Etienne, Florida, FRA
¹⁹IUCT-Oncopole, Hematology Department, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
²⁰Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut Lévêque - Centre François Magendie, Pessac, France
²¹Hematology Department, CHU deToulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

10:30 AM

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Steven Knapper, DM¹, Laura W Dillon, PhD²^*, Malavika Babu³^*, Abin Thomas³^*, Ian Thomas³^*, Christopher S. Hourigan, DM, DPhil⁴, Georgia Andrew, BSc²^*, Richard Dillon, MA⁵, Amanda Gilkes, PhD¹^*, Nuria M Almuina³^*, Sophie King³^*, Thomas Coats, MBBS, PhD, FRCPath⁶^*, Nicholas McCarthy⁷^*, Jennifer Byrne, FRCP FRCPath PhD⁸^*, Simone Green, MBBS, FRCPath⁹^*, Ulrik Malthe Overgaard¹⁰^*, Leanne Berkahn, MD¹¹, Louisa Stone¹²^*, Rasha W Al-Ali¹³^*, Reem Bahr¹⁴^*, Rob Sellar, FRCPath, MBBChir¹⁵^*, Mike Dennis, MD, MRCP, FRCPath¹⁶, Priyanka Mehta, MD, FRCPath, MRCP¹⁷^*, Robert K Hills¹⁸^*, Sylvie D Freeman¹⁹ and Nigel H. Russell, MD²⁰

¹Department of Haematology, Division of Cancer & Genetics School of Medicine, Cardiff University, Cardiff, United Kingdom
²Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD
³Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
⁴Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD
⁵Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
⁶Royal Devon & Exeter NHS Foundation Trust Wonford Site, Exeter, ENG, United Kingdom
⁷University of Birmingham, UK, Birmingham, GBR
⁸Nottingham University Hospitals NHS Trust, Nottingham, GBR
⁹Castle Hill Hospital, Hull, United Kingdom
¹⁰Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
¹¹Haematology Department, Auckland City Hospital, and Australasian Leukaemia and Lymphoma Group, Auckland, New Zealand
¹²Auckland City Hospital, Auckland, New Zealand
¹³Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC
¹⁴Virginia Tech, Charlottesville, VA
¹⁵University College London, London, GBR
¹⁶The Christie NHS Foundation Trust, Manchester, United Kingdom
¹⁷University Hospitals Bristol NHS Foundation Trust, Bristol, GBR
¹⁸University of Oxford, Oxford, GBR
¹⁹University of Birmingham, Birmingham, United Kingdom
²⁰Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

10:45 AM

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai Shimony, MD¹, Heardley Murdock, MD¹, Julia Keating, MS²^*, Christopher R. Reilly, MD¹, Harrison K. Tsai, MD, PhD^3,4^*, Christopher J. Gibson, MD⁵, Stefan Faderl⁶, Tony Wagner⁶^*, Nalina Dronamraju⁶^*, Tara L. Lin, MD⁷, Ellen K. Ritchie, MD⁸, Thomas Prebet, MD, PhD⁹^*, Jorge E. Cortes, MD¹⁰, Geoffrey L. Uy, MD¹¹, Jeffrey E Lancet, MD¹², Donna S. Neuberg, ScD², Richard M. Stone, MD¹ and R. Coleman Lindsley, MD¹

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³Department of Pathology, Brigham and Women's Hospital, Boston, MA
⁴Department of Pathology, Boston Children’s Hospital, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
⁶Jazz Pharmaceuticals, Palo Alto, CA
⁷Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS
⁸Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
⁹Bristol Myers Squibb, Princeton, NJ
¹⁰Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
¹¹Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
¹²Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

617A.O2.6 617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies